Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on Parkinson disease.

Andrew Siderowf1, Matthew Stern

  • 1Parkinson's Disease and Movement Disorders Center, University of Pennsylvania, 330 South 9th Street, Philadelphia, Pennsylvania 19107, USA. adsiderowf@pahosp.com

Annals of Internal Medicine
|April 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychometric Evidence for an Augmented PDAQ for Improved Measurement of Cognition-Related IADLs in Parkinson's Disease.

Movement disorders clinical practice·2026
Same author

Outcomes in Long-Term Follow-Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers Initiative.

Annals of neurology·2026
Same author

Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease.

Annals of neurology·2026
Same author

Sex Differences in Fall Frequency, Risk Factors, and Outcomes in Parkinson's Disease: A Cross-Sectional Analysis.

Movement disorders clinical practice·2026
Same author

How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein Disease.

Annals of neurology·2026
Same author

Return of Individual Research Information in the Parkinson's Progression Markers Initiative.

Annals of neurology·2026

Recent Parkinson disease research highlights environmental and genetic factors, abnormal protein aggregation, and advanced treatments like deep-brain stimulation. This review covers key pathophysiology and therapeutic updates for Parkinson

Area of Science:

  • Neurology
  • Neuroscience
  • Genetics

Background:

  • Parkinson disease pathophysiology and treatment have seen significant advancements.
  • Environmental factors (caffeine, pesticides) and genetic factors are increasingly implicated.

Purpose of the Study:

  • To review recent developments in Parkinson disease pathophysiology and treatment.
  • To synthesize findings on genetic and environmental contributions.
  • To discuss current therapeutic strategies.

Main Methods:

  • Review of recent scientific literature and large-scale epidemiologic studies.
  • Analysis of familial Parkinson disease kindreds.
  • Evaluation of treatment studies for early and advanced disease.

Related Experiment Videos

Main Results:

  • Abnormal protein aggregation is a central pathophysiologic model.
  • Environmental factors like caffeine and pesticides are studied.
  • Genetic factors play a significant role.
  • L-dopa and dopamine agonists have clarified roles in early disease.
  • Deep-brain stimulation shows potential for advanced, refractory Parkinson disease.

Conclusions:

  • Understanding Parkinson disease pathophysiology is advancing through studies of genetics, environment, and protein aggregation.
  • Treatment strategies are evolving, with surgical interventions offering new hope for advanced cases.